Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Harpoon Therapeutics, Inc.

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For more information, please visit www.harpoontx.com.

Invus

Cormorant Asset Management

Commodore Capital

Ally Bridge Group

Soleus Capital

Surveyor Capital

K2 HealthVentures

Lion Point Capital

New Leaf Venture Partners

RA Capital Management

Ridgeback Capital

Arix Bioscience

Taiho Ventures

UBS Asset Management

Lilly Asia Ventures

MPM Capital

NS Investment

oncology impact fund

OrbiMed

Harpoon Therapeutics

Read more about our recent news in our press release here:  https://lnkd.in/d6KUfr3S

We are pleased to announce the promotion of Wendy Chang, GTML™ to Chief People Officer. Ms. Chang joined Harpoon in 2022 as Senior Vice President of Human Resources where she aligned Harpoon’s talent with our strong culture and patient-centric mission. Ms. Chang brings more than twenty years of human resources experience to the role. 

View Our Press Release: https://lnkd.in/eu3dHFGe  

$HARP #immunooncology #TCell #cancer # HPN217 #biotech

Harpoon to present updated interim results from the Phase 1/2 clinical trial of T Cell engager #HPN328 at American Society of Clinical Oncology (ASCO) - Genitourinary Cancers
 
 View full release here: https://lnkd.in/esvmmXBk 
 
#immunooncology #TCell #cancer #biotech #ASCOGU2024

Today we presented the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting and Exposition, and declared 12 mg as the HPN217 recommended Phase 2 dose
 
View full release here: https://lnkd.in/dbh3GJta
 
 $HARP #immunooncology #TCell #cancer #biotech #ASH2023 #RP2D

Now available: our third quarter 2023 financial results. Learn more about the results and highlights here: https://lnkd.in/gESeyRwi 
 
 $HARP #immunooncology #TCell #cancer #HPN217 #HPN328 #biotech #earnings #financialresults

Harpoon announced upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting and Exposition.
 
View full release here: https://lnkd.in/gh-bdiwt
 
 $HARP #immunooncology #TCell #cancer #biotech #ASH2023

Harpoon announced that it has entered into a securities purchase agreement for a #PIPE of up to $150M, led by leading biotechnology investors. 

View full release here: https://lnkd.in/gm-_ci7H

Management hosted a post-ESMO webcast and the replay is available now: https://lnkd.in/gSbKKsgp

#immunooncology #TCell #cancer #biotech #ESMO2023 #financing

Harpoon announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer and other neuroendocrine tumor types in a poster at ESMO - European Society for Medical Oncology Congress 2023

View full announcement here: https://lnkd.in/gt9qhmWZ

Registration for Post-ESMO webcast here: https://lnkd.in/gSbKKsgp 

#immunooncology #TCell #cancer #biotech #ESMO2023

Join Harpoon management for a live webcast reviewing interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in #SCLC and #NEN presented at ESMO - European Society for Medical Oncology Congress 2023

Registration is open now: https://lnkd.in/gSbKKsgp 

View full release here: https://lnkd.in/gt9qhmWZ
 
$HARP #immunooncology #TCell #cancer #biotech #ESMO2023

Harpoon to present interim tolerability and response data from the Phase 1/2 clinical trial of T Cell engager #HPN328 at ESMO - European Society for Medical Oncology
 
View full release here: https://lnkd.in/gPRWbhsC 

$HARP #immunooncology #TCell #cancer #biotech #ESMO23

HARP

NASDAQ:HARP

Harpoon Therapeutics, Inc.

Last Close

22.99

08/03 21:00

Market Cap

865.08M

Beta: 1.55

Volume Today

6.40M

Avg: 270.56K

PE Ratio

−14.03

PFCF: −10.04

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics